UNSPSC 51272003: Thiamylal

This classification denotes a barbiturate and anesthetic agent with the molecular formula C12H18N2O2S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 01T23W89FR, chemically known as 4,6(1h,5h)-pyrimidinedione, dihydro-5-(1-methylbutyl)-5-(2-propenyl)-2-thioxo- (9ci) but generally known as thiamylal, which bears US NIH Compound Identifier 3032285. European Medicines Agency schedules Thiamylal in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB15530MIG.

As of Q4 2014, THIAMYLAL remains the US FDA Preferred Term for this commodity. Thiamylal bears US NLM identifiers UMLS ID C0039855 and NCI Concept Code C66596. SMILES: CCCC(C)C1(C(=O)NC(=S)NC1=O)CC=C.

UNSPSC 51272003 Thiamylal is a Commodity code that nominally covers a specific barbiturate pharmaceutical, but recent state and local procurement activity under this code shows substantial divergence from the narrow product scope. State and local governments are using this code to solicit a much broader range of pharmaceutical products and related health-system supplies, including naloxone (opioid antagonist), drug deactivation systems, generic multi-source pharmaceuticals, and over-the-counter products. The issuing bodies include county health departments (Seminole County, Florida), state health and human services commissions (Texas HHS), and multistate cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance, serving Minnesota, Oregon, and other participating jurisdictions). The work being solicited spans direct pharmaceutical supply, pharmacy benefit program management, and support for community health initiatives addressing opioid response and substance abuse prevention.

Activity is concentrated in three states: Florida (Seminole County's naloxone and drug deactivation systems procurement), Texas (Texas HHS Commission's RFI on direct-to-manufacturer prescription programs), and Minnesota (MMCAP's multistate generic pharmaceuticals and OTC products RFP). The most recent solicitations include Seminole County's IFB 60459723LAS, posted June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries and a July 26, 2023 response deadline; the Texas HHS Commission's RFI HHS0017013, posted April 3, 2026, gathering vendor capabilities for a direct-to-manufacturer prescription program with no immediate award; and MMCAP's RFP S1070000015802, posted January 20, 2026, establishing multiple contracts for generic pharmaceuticals and OTC products with a March 26, 2026 proposal deadline and July 1, 2026 contract start date. The code shows low signal as a reliable procurement marker for a narrow-scope pharmaceutical product—recent opportunities suggest that state and local health systems are tagging broader pharmaceutical procurement and health-initiative work under this code, indicating potential indexing drift or systematic misclassification at the point of solicitation posting.